BioCardia, Inc. BCDA 深 沪
等待开盘 01-12 09:30:00 美东时间
1.405
+0.085
+6.44%
华盛通- 最 高1.41
- 今 开1.32
- 成交量 11.76万股
- 最 低 1.32
- 昨 收 1.32
- 总市值 1491.08万
- 52周最高 3.20
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 1.00
- 委 比 -12.94%
- 总股本 1061.27万
- 历史最高 129.00
- 量 比 1.68
- 振 幅 6.82%
- 历史最低 1.00
- 每 手 1
- 风险率 0.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioCardia Completes Third Preliminary Clinical Consultation With Japan's PMDA On CardiAMP Cell Therapy Intended For Treatment Of HFrEF
BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary clinical consultation
2025-12-16 21:08
BioCardia Q3 EPS $(0.24) Beats $(0.25) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 60.66 percent increase over losses of $(0.61) per share from the same
2025-11-13 05:13
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
BioCardia reported Q3 2025 financial results and filed its 10-Q with the SEC. The company secured $6 million financing to support CardiAMP cell therapy approvals and the Helix delivery catheter submission. Clinical trials for CardiAMP in heart failure and chronic myocardial ischemia showed positive results, with ongoing enrollment in the Phase 3 CardiAMP HF II trial. The company plans a conference call to discuss these milestones.
2025-11-12 21:40
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
Earnings Outlook For BioCardia
BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on ...
2025-11-12 02:03
BioCardia shares are trading higher. The company recently announced University of Wisconsin enrolled first patient in phase 3 CardiAMP HF II cell therapy pivotal trial.
BioCardia shares are trading higher. The company recently announced University ...
2025-10-31 23:39
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
BioCardia, Inc. announced the first patient enrollment at the University of Wisconsin School of Medicine and Public Health in its Phase 3 CardiAMP HF II clinical trial for ischemic heart failure patients. The study aims to confirm the safety and efficacy of CardiAMP autologous cell therapy, which uses the patient's own bone marrow cells to improve cardiac function. BioCardia and UW partners expressed optimism about the trial's potential to advanc...
2025-10-30 12:00
BioCardia Updates ATM Offering, Raising Maximum Aggregate Sale To $5,309,253
This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplemented by our prospectus supplement dated December 6, 2023, as further supplemented by the
2025-10-25 04:26
BioCardia Sets Record Date for Annual Meeting
BioCardia ( ($BCDA) ) just unveiled an announcement. BioCardia, Inc. has announ...
2025-10-08 04:52
BioCardia regains Nasdaq compliance after balance sheet improvements; shares up
BioCardia (NASDAQ:BCDA) has regained compliance with Nasdaq listing requirements. On October 1, 2025, Nasdaq confirmed BioCardia now meets the Equity Rule. Compliance follows efforts to strengthen the...
2025-10-02 20:23
